Health Secretary Robert F. Kennedy Jr.'s effort to relax federal rules on peptides is reshaping the landscape for companies betting on the next big health trend. The move could unlock a multibillion-dollar market that telehealth platforms, compounding pharmacies, and longevity clinics are rushing to capture.
Peptides, short chains of amino acids, have already developed a devoted following among fitness enthusiasts and celebrities seeking remedies for injuries, inflammation, and aging. Social media influencers and podcasters including Joe Rogan have amplified the buzz, with Rogan notably hosting Kennedy in February to discuss his agenda and reveal his personal use of the products.
The FDA is scheduled to convene an advisory panel in July to determine whether compounding pharmacies can manufacture certain peptides. The agency is also unwinding a Biden-era policy that barred such production, opening a direct path for regulatory loosening.
One candidate gaining attention is BPC-157, derived from human gastric juice and promoted for injury healing based on animal studies. Chris Shade, CEO of Quicksilver Scientific, which produces oral peptide versions, called them "the most potent things that we've seen in health care since hormones."
Analysts see massive financial upside. The peptide market currently sits at roughly $60 billion globally and could reach $180 billion within five years if regulatory barriers fall, according to Kate Festle, a managing director at West Monroe consultants. Companies like Hims & Hers and Ro already possess the infrastructure to rapidly prescribe and deliver these treatments directly to consumers. Hims acquired a peptide manufacturing facility last year, and the prospect of FDA rule changes sent its stock climbing nearly 50 percent in a single week.
But the boom carries real medical risks. Eric Topol, executive vice president of Scripps Research, raised concerns about cancer and other health dangers linked to how peptides stimulate hormone production and tissue formation. He also flagged uncertainty around interactions when multiple peptides are taken together, or when combined with other medications.
"The FDA should ban these peptides from being imported, from being used, and force the companies that are making huge amounts of profit on them to do the proper studies," Topol said.
Unlike branded GLP-1 weight-loss drugs, most peptides have not undergone clinical trials. The current unregulated expansion has been turbocharged by influencers promoting the products without adequately addressing potential harms, Topol noted. "I'd love to see therapies that help people. Just show me the data," he said.
Industry players are pushing back against calls for stricter regulation. Some advocate for a middle path that would expand access while adding oversight, rather than subjecting peptides to the traditional drug approval process. Shade has proposed treating naturally occurring peptides as dietary supplements.
The uncertainty extends beyond safety. Success hinges on consumer demand, regulatory decisions, and whether the hype surrounding peptides can sustain momentum as more products flood the market. For now, the infrastructure is building, the momentum is real, and the race to dominate the space has begun.
Author James Rodriguez: "Kennedy's deregulation push could make peptides the next unproven wellness craze to go mainstream, and that's a problem when the science lags this far behind the marketing."
Comments